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Blood hormone and tumor marker concentrations are usually determined by immunochemical methods which are based on
an unique reaction between antigen and assay capture antibody. Despite the speed and simplicity of assays performance on
automatic immunochemistry platforms, the interpretation of ﬁnal results requires a deep knowledge of method fallibility. General
lack of immunoassays standardization, presence of cross-reacting substances in patient’s sample, limitation of free hormones
measurement due to abnormal analyte binding protein concentrations, assay interferences due to patient’s autoantibodies, and
heterophilic antibodies, as well as proper interpretation of very low- and very high-sample analyte levels, are the main points
discussed in respect to hormones and tumor markers measurement in geriatric population.
1.Introduction
Aging process is associated with physiological changes in
function of almost every organ and system, including the
endocrine system. The function of endocrine glands func-
tion declines progressively with age. For example, dehydroe-
piandrosterone sulphate (DHEAS) concentration is about
10–20% of maximum in patients at the age of 70–80 years
[1]. The activity of the growth hormone/IGF axis also de-
clinessteadily,andasuddencessationofthefunctionofsome
elements of the hormonal system is well documented [2–
5]. Negative feedback loop is the common regulatory mech-
anism within endocrine system. Thus, markedly decreased
or markedly increased blood hormones concentrations can
be measured in elderly patients. Multiple diseases, which
frequently entail polytherapy with the use of multiple drugs,
inﬂuence the levels of hormones in vivo and the measure-
ment biomarkers as well as drugs concentration by immuno-
chemistry in vitro [6]. The coexistence of multiple diseases
may cause secondary changes in hormone levels as it is the
case with the level of thyroid-stimulating hormone (TSH) in
nonthyroidal diseases [7–9]. Moreover, in an elderly popula-
tion, the presence of autoantibodies due to autoimmune or
chronic diseases is more frequent than it is in the younger
population. The presence of autoantibodies in the plasma or
serum, like rheumatoid factors (RFs), may aﬀect the deter-
mination of many hormones by immunochemistry, or if
directed against a speciﬁc molecule, such as prolactin or
troponin, they may mislead the medical decision based on
hormone measurement [10–13]. In addition, changes in the
serum level of speciﬁc and nonspeciﬁc hormone-binding
protein, especially albumin, frequently observed in geriatric
population, greatly inﬂuence the measurement of free hor-
mones [14]. Furthermore, the fallibility and limitation of
immunochemical methods of hormone measurements may
lead to clinically misleading interpretation of laboratory
results of hormone concentration in elderly population.
Hormones,proteins,peptides,tumormarkers,anddrugs
are routinely measured using automated immunochemistry
platforms. Immunochemistry methods are based on the
reaction between an antigen and an antibody; both competi-
tive and noncompetitive method formats are used. The reac-
tionbetweenantigenandantibodyisveryspeciﬁcduetouni-
que properties and stereochemistry of epitope on the antigen
and paratope on the antibody. Although the analytical
procedure for measuring hormones is very simple and easy2 International Journal of Endocrinology
to perform, the interpretation of results requires not only
medical knowledge but also deep knowledge of immuno-
chemistry limitations. This is especially true when hormone
measurements are performed in the serum of the patient
at an extremely advanced age, the patient with multiple or
chronic disease, and the patient on multiple drugs therapy.
For all the laboratory determinations, the preanalytical
phase of a diagnostic procedure contributes the most to
the total laboratory error of measurement, regardless of the
patient’sage.Thetypeofanticoagulantsused,thepresenceof
hemolysis, lipemia, hyperbilirubinemia, and paraproteine-
mia are well-known factors, inﬂuencing the measurement
of biochemical markers, including hormones. The observed
bias due to hemolysis may be negative, as it is the case
with cortisol, parathyroid hormone (PTH), and insulin
measurement, or positive as it is the case with troponin I
determination [15, 16]; or susceptibility to interference by
hemolysis is diﬀerent, as it was shown for cardiac troponin
I and troponin T measured by current immunoassays [17].
Some hormones are very labile ex vivo, and negative bias
due to proteolysis is frequently seen in the measurement of
peptides, such as adrenocorticotropic hormones (ACTH),
insulin, osteocalcin, C-peptide, and PTH [18, 19]. Although
the concentrations of most hormones are measured directly
in the serum or plasma, it is necessary for many hormones to
treat the blood sample speciﬁcally before analysis, as in the
case of gastrointestinal peptides measurement [20, 21].
Apart from the aforementioned pre non-speciﬁc analyti-
calproblems,therearemanypitfallswhichmayoccurduring
theanalyticalphaseofhormonesdeterminationbyimmuno-
chemical methods, which are known by the laboratory per-
sonnel but frequently unknown by physicians. For a proper
interpretation of the hormone concentration results, the
comparison of the results with appropriate reference inter-
vals coupled with good clinical knowledge is necessary. In
case of discrepancy between the laboratory data and the clin-
ical picture of the patient, repeated analytical measurements
are usually requested. However, in the case of hormones
and tumor markers, repeated measurements of the analyte
by immunochemistry in questionable patients’ samples give
concentration results that do not always meet clinical expec-
tations. To avoid such a situation, it is important for clini-
cians to know and to understand the limitation and fallibility
of immunochemical methods in order to protect the patient
from misdiagnosis. This is extremely important for every
patient, but it must be stressed that in samples from geriatric
patients, the presence of various drugs and their metabolites,
the presence of autoantibodies and other inducible antibod-
ies, and low albumin level, as well as disturbances in speciﬁc
and nonspeciﬁc hormone-binding protein levels, are fre-
quently observed. In addition, tumor marker measurements
are much more frequently requested in older patients as
compared to other age groups, extremely high level of some
proteins can be expected as well. On the other hand, after
surgery of the endocrine gland due to cancer, or during sup-
pressive therapy, the measurement of very low level of some
hormonesisimportantforclinicalmanagementofageriatric
patient. Thus, for proper interpretation of the laboratory
results of hormones and tumor markers determination, it is
advisableforphysicianstobecomefamiliarwithmostimpor-
tant immunochemistry issues, so that they could answer
the following questions: (a) what is being measured by a
given immunoassay? (b) how accurate are low and high con-
centrations of hormone/tumor marker measured? (c) how
do binding proteins aﬀect hormone measurement? (d) how
do autoantibodies; heterophilic and anti-animal antibodies
interfere with the measurement of hormone/tumor marker?
1.1. What Is Being Measured by the Immunoassay? Diﬀerent
chemical molecules, such as protein, peptides, biogenic
amines, steroids, and drugs, can be measured by immuno-
chemical methods. As for any other methods, standardiza-
tion of immunochemical methods is necessary to ensure
accuracy of a measurement and comparability of results
between diﬀerent assays. However, most of the immunoas-
says lack proper standardization. Although the primary
standards are available for small molecules (amines, steroids,
and drugs), the lack of commutability between primary or
secondary standards and the patient’s samples due to matrix
eﬀect make the standardization process a very diﬃcult task.
On the other hand, many hormones of clinical interest
are present in the blood in heterogeneous forms (growth
hormone, prolactin, gonadotropins, TSH, and gastrin) [22–
25] or in monomeric and dimeric forms (insulin) [26, 27].
For heterogeneous molecules, the exact deﬁnitions of the
substance intended to be measured by immunoassay should
always be speciﬁed by manufacturers because depending
on the speciﬁcity of antibodies used in immunochemical
methods, diﬀerent forms of protein can be measured [28]. In
addition, plasma samples contain a vast variety of molecules,
and there is always a possibility that a chemical structure
recognized by an immunoassay capture antibody can be
found not only on the molecule of interest, but also on
“cross-reacting” substances. Heterogeneity of proteins and
their structural similarity and the presence of cross-reacting
substances in patients’ samples can be a source of false posi-
tive(competitivemethods)orfalsenegative(noncompetitive
methods) results [28–31]. In case of heterogenous proteins,
harmonization can be used to improve comparability of
methods. The purpose of the harmonization process is to
obtain similar results for the analyte measured by diﬀerent
“harmonized” immunoassays calibrated with the use of the
same calibrator. It has to be stressed out that harmonization
of methods is not equivalent to method standardization.
Immunochemical methods for the measurement of the
same analyte may diﬀer with respect to reagent antibodies
and to a diﬀerent standard for calibration. As a consequence,
the results of the concentration of hormones and tumor
markers obtained by diﬀerent assay or immunochemistry
platforms are often not comparable. Thus, two issues are of
great importance: ﬁrstly, the knowledge of the molecule that
isbeingmeasuredbyimmunoassay;secondly,themandatory
use of the method-dependent reference intervals established
bythelaboratory.Takingintoaccountthelackofimmunoas-
says standardization, heterogeneity of many peptides and
protein, structural similarities of steroids and their metabo-
lites, as well as capture antibody speciﬁcity, the request forInternational Journal of Endocrinology 3
the hormone or tumor marker measurement by two labora-
tories using diﬀerent immunoassays should be avoided.
1.2. How Accurate Are Low and High Concentrations of the
Hormone/Tumor Marker Being Measured? Analytical sensi-
tivity is an important issue for those analytes for which low
concentrations in the patient’s sample are diagnostically im-
portant as it can be observed in geriatric population in case
of C-reactive protein (CRP), estrogen, TSH, and troponin
measurement [32–35]. Interpretation of very low concentra-
tions of some analytes requires understanding the analytical
sensitivity which, in the simplest way, can be deﬁned as the
lowest hormone concentration that can be determined by
a given method. From the clinical point of view, it is not
enough to accept the limit of the absence of the analyte in
the sample based on a repeated zero standard measurement
and taking the mean value plus two or three standard devia-
tions. Since each analytical measurement is burdened with
error, it is important to know what is the limit of analyte
quantiﬁcation (functional sensitivity of the method). For
proper interpretation of a low analyte level, it is necessary to
know the concentration value that is measured with certain,
predeﬁned precision, usually 10–20%. Many methods are
not sensitive enough to measure, for example, low estrogen
level (characteristic for pediatric population, men and post-
menopausal women) or TSH in geriatric population with
nonthyroidal illnesses. It should be noted that a laboratory
cannot determine the concentration of any analyte below the
functionalsensitivity with acceptableprecision and accuracy,
and any approximation of standard curve below the value of
concentration determining functional sensitivity is the unac-
ceptable analytical practice. It is especially important when
C-reactive protein (CRP) is not measured by highly sensitive
CRP method (hsCRP), and clinical judgment is made on the
basis of the CRP level as a prognostic factor in a geriatric pa-
tient.ThemeasurementofCRPbytwoimmunoassaysdiﬀer-
ing in analytical sensitivity and using the results interchange-
ably, that is, both as an inﬂammatory marker and a prognos-
tic marker of future cardiovascular events should never be
done. Another example showing the importance of functi-
onal sensitivity in geriatric population is troponin measure-
ment, since a very small increase in its concentration may
have serious clinical consequences [36]. Each laboratory that
measures troponin level should have functional sensitivity
established under routine conditions, and physicians should
be aware of such concentration value in order to avoid pa-
tient misdiagnosis.
Measurement of very high or extremely high concentra-
tion of hormones and tumor markers is a great challenge
for laboratory staﬀ, since disagreement between the clinical
picture of the patient and the laboratory result is sometimes
noted. This is especially true for a geriatric population be-
cause the frequency of oncologic diseases of diﬀerent origin
increases with age. In immunochemical noncompetitive
methods, unlike in other analytical methods, a high-dose
eﬀect (hook eﬀect) may occur. In such methods, antigen is
linked with two assay antibodies (solid-phase capture anti-
body and signal antibody) forming a so-called “sandwich”,
and the proportionality between the assay signal and analyte
concentrationisseen.However,theenormousamountofthe
analyte in the patient’s sample blocks both assay capture and
labeled antibodies, which does not allow for the formation
of a typical “sandwich” [28]; and the linear relationship be-
tween the magnitude of the assay signal and the concentra-
tion of analyte no longer exists. As a consequence, assay sig-
nal is descending. This means that the same assay signal is
obtainedforthelowandtheveryhighanalyteconcentration.
As a result, falsely low, frequently normal, concentration of
the analyte is measured [37]. This eﬀect occurs more freque-
ntlyin homogenousnoncompetitive assayscomparedtohet-
erogeneous noncompetitive assays. If hook eﬀect is sus-
pected,eachlaboratoryperformsthedilutiontestuntilstable
assay signal is obtained. Erroneous results due to hook eﬀect
can be observed, among others, for carcinoembryonic anti-
gen (CEA), alpha-fetoprotein (AFP), prostate-speciﬁc anti-
gen (PSA), prolactin, thyroglobulin, and cancer-antigen CA-
125 [38–44]. Requesting the tumor marker measurement,
either for the patient diagnosis or for monitoring therapy,
and suspecting the hook eﬀect in an oncologic patient are
of great importance because only the abnormal concen-
tration results (outside reference intervals) alert laboratory
personnel and physicians; the results within normal range
or below cutoﬀ points rarely undergo additional laboratory
procedure, unless there is a disagreement between the
laboratory result and the patient clinical condition.
1.3. How Do Binding Proteins Aﬀect Hormone Measurement?
In the geriatric population, the results of hormones mea-
surement should be interpreted with caution as age-related
decline in concentration is characteristic not only for speciﬁc
binding proteins, such as insulin-like growth factor-binding
protein 3 (IGFBP-3), but also for nonspeciﬁc binding
proteins, such as albumin [45–47]. It may be expected that
decreased serum albumin concentration is related to aging;
however, it is caused more often by chronic malnutrition
than by aging itself [48]. Prolonged decrease in albumin
concentration is characteristic of liver and kidney disease,
congestive heart disease, and protein-losing enteropathies.
Inﬂammation, frequently seen in elderly population, is
another cause of low albumin level, as albumin is a negative
acute-phase protein [49]. Changes in speciﬁc levels of
hormone-binding proteins inﬂuence the discrete equilib-
riumwhichexistsbetweenboundandfreehormonefraction.
Changesinnonspeciﬁcbindingproteinconcentrationdonot
only inﬂuence the balance between free and bound fraction
of hormone but also have a great impact on the plasma level
of many biochemical parameters as these proteins bind and
release diﬀerent ligands, changing the sample matrix. This
is especially true for albumin, which is an universal carrier
for drugs, metals, fatty acids, vitamins, steroids, minerals,
and hormones; binding/releasing diﬀerent ligands strongly
depends on pathological condition [50–53].
A good example of the eﬀect of binding proteins on
hormone determination is the estimation of free-thyroid
hormone levels (FT4 and FT3) in elderly population. The
FT4 plasma concentration depends on the binding capacity
of thyroxine-binding globulin concentration (TBG) as well
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format, either false positive (competitive methods) or false
negative (noncompetitive methods) results of free hormone
measurementcanbeobtainedasaneﬀectofbindingproteins
interference [28]. Interpretation of FT4 is also diﬃcult in a
female patient on estrogen therapy because estrogen excess
is associated with a rise of TBG concentration as well as in
a patient on androgen therapy in whom a marked decreased
TBG level is observed [54].
In geriatric patients treated with heparin (including low-
molecular-weight heparin), a misleading diagnosis can aﬀect
the patients’ safety due to falsely elevated FT4. The concen-
tration of FT4 in such patients depends on the time that
elapsed between heparin administration and blood sampling
as well as the time that elapsed between the collection of the
bloodandperformingimmunoassaymeasurement[55].Free
fatty acids released due to in vitro lipolysis displace T4 from
its binding protein complexes. Thus, a false increase in FT4
concentrationisseen.Inrelationtothis,intheinterpretation
of hormone level in the plasma in both free and bound frac-
tion, a low albumin level should always be taken into consi-
deration.
Lower serum albumin level frequently observed in geri-
atric population is also associated with the decrease in max-
imum binding capacity of drugs, which is signiﬁcant during
polytherapy. As a consequence, free-drug concentrations in
the plasma are increased [56]. Common drugs used in the
geriatric population strongly bind to plasma protein (tri-
cyclic antidepressants, psychotropic medications, benzodia-
zepines, phenytoin and warfarin). Hence, any disturbance in
binding proteins inﬂuences the plasma drug concentration
measured by immunochemistry.
1.4. How Do Autoantibodies, Heterophilic, and Anti-Animal
Antibodies Interfere with Hormone/Tumor Markers Measure-
ment? Common health problems encountered in the geri-
atric population include various chronic inﬂammatory dis-
eases such as rheumatoid arthritis, pneumonia, and systemic
lupus erythematosus (SLE) [57–60]. In such conditions, the
presence of diﬀerent autoantibodies in the blood is observed,
and the prevalence of increased concentration of autoanti-
bodies increases with age [61, 62]. Changes in the immune
system are associated with a high incidence of antibodies
such as rheumatoid factors (RFs), antinuclear antibodies
(ANA),antibodiesagainstsingle-strandDNA(ssDNA),anti-
bodies against double-strand DNA (dsDNA), antiphospholi-
pid antibodies, antibodies against hormones (i.e., antibodies
againstinsulin),andanty-IGFBP2antibodies[61].Inplasma
samples, they represent a large variation in titer at diﬀerent
periods of time, depending on the patient’s disease stage. In
thegeriatricpopulation,thepresenceoforganandnonorgan
speciﬁc autoantibodies is common; and frequently, no visi-
ble symptoms of disease are seen [61]. Autoimmune thyroid
disease is a frequent pathology in geriatric patients which
includes Graves’ disease, Hashimoto’s thyroiditis, hyperthy-
roidism, and hypothyroidism. Therefore, increased levels of
autoantibodiesagainstthyroglobulin(antyTg),autoantibod-
ies against thyrotropin receptor (TRAB), and antithyroid
peroxidase antibodies (anti-TPO) are also noted [63].
From the analytical point of view, diﬀerent problems
havetobeconsideredifitisnecessarytomeasuretheconcen-
trationofproteinagainstwhichautoantibodiesarepresentin
the plasma sample or measurement of autoantibodies as an
independent marker of immune disease is requested. Firstly,
autoantibodies can interfere with the analyte measurement,
giving erroneous results and, depending on the assay for-
mat, both underestimation (noncompetitive methods) or
overestimation (competitive methods) can be observed [28].
The most typical example is the thyroglobulin concentration
measurementinthepresenceofantithyroglobulinantibodies
in a patient with diﬀerentiated thyroid carcinoma [64–67].
Secondly, if the level of autoantibodies is to be measured,
ﬁnalresultsdepend,toalargeextent,ontheamountofendo-
genous self-antigen already bound to autoantibodies and
frequently, no agreement between competitive and noncom-
petitive immunoassay formats is achieved. Thirdly, human
immunoglobulin frequently forms a complex with the target
proteinintended tobemeasured,formingaso-calledmacro-
protein. The complex of prolactin with immunoglobulin is
one of the well-recognized protein macroform by endocri-
nologists. A complex of monomeric protein with immu-
noglobulin, usually IgG, may not be active in vivo but can be
immunoreactive,soitcanbedetectedbyimmunoassays[28].
Itisassumedthatmacroproteinhasnobiologicalactivity,but
its half-life is much longer than the half-life of monomeric
protein. Thus, macroprotein accumulates in the blood.
Depending on the immunoassay format, both free and com-
plexed forms of protein may be detected by the immunoa-
ssay or only the free form is measured but with macroprotein
invisible by the assay antibody. Recently, analytical problems
connecting the measurement of troponin in a sample in the
presence of autoantibodies against troponin T and troponin
I have been discussed in the literature [68–70]. Since the fre-
quency of protein macroform formation increases with age,
it is important to take such interference into consideration in
case of disagreement between clinical picture of patient and
laboratory immunoassay result.
In addition to autoantibodies against self-antigens, any
inducible antibodies against diﬀerent foreign antigens can be
present in human serum samples. Such inducible antibodies
are usually polyreactive and are directed against poorly
deﬁned foreign antigens. For analytical purposes they have
been called heterophilic antibodies. The best known het-
erophilic antibodies are rheumatoid factors [71]. In serum
or plasma samples, human anti-animal antibodies pro-
duced against antigen of animal origin, such as human anti-
mouse antibodies (HAMA) or human anti-rabbit antibodies
(HARA), can also be present [72–74]. Both human hetero-
philic and human anti-animal antibodies have properties
similar to autoantibodies with respect to binding to immun-
oassay reagent antibodies [75]. This means that these human
antibodies have the ability to interfere in an immunoassay
reaction by binding to reagent assay antibodies (animal ori-
gin, usually mouse monoclonal antibody) either by binding
to the epitope or by sterically blocking the access of antigen
to the binding site. The type, amount, and aﬃnity of hu-
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a patient’s sample are usually unknown and variable [76–
79]. The mechanism of heterophilic antibody interference
depends on the assay format; both falsely elevated, falsely
positive, and falsely decreased results can be obtained. It is
impossible to predict the mode of reaction between assay
reagent antibodies and interfering antibodies just as it is
almost impossible to judge a priori in which patient’s sample
interference will occur.
In the geriatric population, interference from hetero-
philic antibodies is as extremely important as the variety of
antibodies that are present in the blood. For example, rheu-
matoid factors are present in 70% of patients with rheuma-
toid arthritis and the occurrence of human anti-mouse anti-
bodies as a consequence of treating the patient with mouse
immunoglobulin for diagnostic and therapeutic purposes is
estimated as high as 11.7% [80]. In the literature, a plethora
of papers describe the unexpected interference from anti-
animal antibodies, for example, in the PTH measurement in
serum sample of a patient treated with murine monoclonal
antibodydirectedtowarddiﬀerentsurfaceantigensofhuman
T-cell immunoglobulin [81]. It is expected that the problem
of interference from heterophilic and human anti-mouse
antibodies will increase as new therapeutic approaches for
cancer treatment are introduced.
2. Conclusions
Accuracy of analytical measurement of diﬀerent biochemical
parameters is a prerequisite for proper diagnosis and treat-
ment monitoring of the patient. Immunochemical methods
play an important role in measurement of a variety of bio-
chemical molecules, although due to their fallibility, many
limitations in measurement are noted. Immunochemistry is
a very powerful analytical technique, but imperfections in
analytical measurement are directly connected with unique
basis of methods, general lack of standardization, and prese-
nce of many interfering substances in patients’ samples. The
more a patient’s sample matrix diﬀers from the normal sam-
ple matrix, the higher the probability that erroneous results
will occur. In older patients, misinterpretation of immuno-
chemistry results due to the presence of interfering endoge-
nous substances (cross-reacting substances, abnormal hor-
mone binding proteins, presence of autoantibodies, het-
erophilic antibodies, and anti-animal antibodies) in the
blood is more frequent than in younger individuals. It has
to be stressed, that most pitfalls in analyte measurement by
immunochemistry are related to a patient’s sample, and no
quality control assurance program exists to protect patient
from erroneous results. The only way to suspect an error
in immunochemistry results is through the information
obtained from physicians, where there is disagreement
between laboratory results and the patient’s condition. Each
laboratory has procedures to look for errors in immuno-
chemistry measurement, but the information must ﬁrst
come from clinicians. The more signals from physicians, the
higherthepossibilityinavoidingimmunochemistryerrorsin
the future. In order to achieve this, the physician taking care
of the geriatric population should be familiar with the limi-
tations of immunochemistry.
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